Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Gynecologic Oncology
|
December 21, 2016
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
Gennaro Daniele, Domenica Lorusso, Giovanni Scambia, et al.
Cancers
|
April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients
Crescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 3, 2012
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials
Massimo Di Maio, Simona Signoriello, Alessandro Morabito, et al.
International Journal of Cancer
|
August 26, 2025
Circulating fatty acid binding protein 4 (FABP-4) concentrations and mortality in individuals with colorectal cancer in the European Prospective Investigation into Cancer and Nutrition study
Thu Thi Pham, Katharina Nimptsch, Krasimira Aleksandrova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
Cesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials
Alessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 17, 2012
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer
Massimo Di Maio, Natasha B Leighl, Ciro Gallo, et al.
Oncotarget
|
September 23, 2016
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
Francesco Perrone, Gustavo Baldassarre, Stefano Indraccolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Gynecologic Oncology
|
December 21, 2016
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
Gennaro Daniele, Domenica Lorusso, Giovanni Scambia, et al.
Cancers
|
April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients
Crescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 3, 2012
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials
Massimo Di Maio, Simona Signoriello, Alessandro Morabito, et al.
International Journal of Cancer
|
August 26, 2025
Circulating fatty acid binding protein 4 (FABP-4) concentrations and mortality in individuals with colorectal cancer in the European Prospective Investigation into Cancer and Nutrition study
Thu Thi Pham, Katharina Nimptsch, Krasimira Aleksandrova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
Cesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials
Alessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 17, 2012
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer
Massimo Di Maio, Natasha B Leighl, Ciro Gallo, et al.
Oncotarget
|
September 23, 2016
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
Francesco Perrone, Gustavo Baldassarre, Stefano Indraccolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
Page
of 6